202 related articles for article (PubMed ID: 33212461)
41. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.
Willson RA
J Clin Gastroenterol; 2002 Jul; 35(1):89-92. PubMed ID: 12080234
[TBL] [Abstract][Full Text] [Related]
42. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C.
Schäfer M; Boetsch T; Laakmann G
Addiction; 2000 Jul; 95(7):1101-4. PubMed ID: 10962774
[TBL] [Abstract][Full Text] [Related]
43. [Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C].
Nakamura T; Takahashi H; Koike N; Mitsutaka M; Soda M; Kimu M
Nippon Ganka Gakkai Zasshi; 2005 Nov; 109(11):748-52. PubMed ID: 16363669
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Pellicelli A; Grisorio B; Barbarini G
J Hepatol; 2000 Sep; 33(3):448-55. PubMed ID: 11020001
[TBL] [Abstract][Full Text] [Related]
45. Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C.
Tappero G; Ballaré M; Farina M; Negro F
J Hepatol; 1998 Dec; 29(6):1033-4. PubMed ID: 9875657
[No Abstract] [Full Text] [Related]
46. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
[TBL] [Abstract][Full Text] [Related]
47. [Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?].
Steimann RU; Bode JC
Versicherungsmedizin; 2000 Mar; 52(1):24-7. PubMed ID: 10718088
[TBL] [Abstract][Full Text] [Related]
48. Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C.
Wendling J; Descamps V; Grossin M; Marcellin P; Le Bozec P; Belaich S; Crickx B
Arch Dermatol; 2002 Apr; 138(4):546-7. PubMed ID: 11939833
[No Abstract] [Full Text] [Related]
49. Chronic viral hepatitis C: management update.
Gutfreund KS; Bain VG
CMAJ; 2000 Mar; 162(6):827-33. PubMed ID: 10750473
[TBL] [Abstract][Full Text] [Related]
50. [A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin for chronic hepatitis C].
Watanabe T; Inoue M; Harada K; Homma N; Uchida M; Ogata N; Funada R; Hasegawa K; Soga K; Shibasaki K
Nihon Shokakibyo Gakkai Zasshi; 2006 Sep; 103(9):1061-6. PubMed ID: 16953104
[TBL] [Abstract][Full Text] [Related]
51. [Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].
Chebil A; Kort F; Bouraoui R; Youssef NB; El Matri L
J Fr Ophtalmol; 2010 Mar; 33(3):185-8. PubMed ID: 20172621
[TBL] [Abstract][Full Text] [Related]
52. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].
Lee YN; Jeong SW; Lim JH; Ryu YS; Jeon SR; Kim SK; Jang JY; Kim YS; Kim BS; Roh MO
Korean J Hepatol; 2010 Jun; 16(2):187-91. PubMed ID: 20606504
[TBL] [Abstract][Full Text] [Related]
53. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
54. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
Enjoji M; Dainichi T; Gondo H; Urabe K
Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
[TBL] [Abstract][Full Text] [Related]
55. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
[No Abstract] [Full Text] [Related]
56. Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
Bektas M; Bektas H; Gören D; Altan M; Cetinkaya H
Digestion; 2007; 75(4):208-9. PubMed ID: 17934275
[No Abstract] [Full Text] [Related]
57. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.
Dieperink E; Ho SB; Thuras P; Willenbring ML
Psychosomatics; 2003; 44(2):104-12. PubMed ID: 12618532
[TBL] [Abstract][Full Text] [Related]
58. Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort.
Predescu O; Streba LA; Irimia E; Streba L; Mogoantă L
Rom J Morphol Embryol; 2012; 53(3):497-502. PubMed ID: 23010773
[TBL] [Abstract][Full Text] [Related]
59. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.
Gaeta GB; Precone DF; Felaco FM; Bruno R; Spadaro A; Stornaiuolo G; Stanzione M; Ascione T; De Sena R; Campanone A; Filice G; Piccinino F
Aliment Pharmacol Ther; 2002 Sep; 16(9):1633-9. PubMed ID: 12197842
[TBL] [Abstract][Full Text] [Related]
60. [Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].
Christensen UB; Krogsgaard K
Ugeskr Laeger; 2004 Mar; 166(11):1024-5. PubMed ID: 15049242
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
